Modus presented at SCD Therapeutics Conference in New York 2017

Modus CEO Ellen K Donnelly presented at Annual Sickle Cell Disease Therapeutics Conference 2017

In her presentation, Dr Donnelly reviewed Modus Therapeutics’ strategy and presented the clinical development plans for sevuparin, a novel drug that could become a treatment option for patients with SCD. Sevuparin has the potential to normalize the lives of SCD patients reducing the severity and duration of pain associated with the vaso-occlusive crisis (VOC).  In addition, sevuparin may be beneficial by:

  • Shortening hospital stays which result from an acute vaso-occlusive crisis (VOC); or
  • Reducing the need for hospitalization via SCD patients being able to self-administer the drug when they believe a VOC is imminent

The Company is continuing the enrolment of patients into a Phase II study that is assessing its lead candidate sevuparin for the treatment of SCD.  The Phase II study, which is being conducted in Europe and the Middle East (NCT02515838), is expected to report in 2018.

The Annual Sickle Cell Disease Therapeutics Conference is a forum to discuss the latest advances and future trends in treating patients with sickle cell disease. The event will feature presentations from clinical-stage companies, key opinion leaders, patients and healthcare analysts.